ASCO 2021: Summary Overview and Outlook 16 | The potential role of ctDNA in predicting colorectal cancer recurrence and overall management

At present, the main challenge of colorectal cancer (CRC) treatment is to be able to detect the recurrence of patients after surgery in time, and to identify patients who are at high risk of recurrence after surgery and adjuvant therapy (ACT).

At present, the main challenge of colorectal cancer (CRC) treatment is to be able to detect the recurrence of patients after surgery in time, and to identify patients who are at high risk of recurrence after surgery and adjuvant therapy (ACT).

ASCO ctDNA test to evaluate colorectal cancer

The purpose of this prospective multi-center study is to determine whether the use of ctDNA testing after multiple operations can identify high-risk relapsed patients, detect relapse earlier than standard radionuclide imaging, and evaluate adjuvant therapy.

This cohort study included 265 patients with clinical stage I-III colorectal cancer, and it is also the largest cohort evaluated for ctDNA testing to date.

Adjuvant Therapy (ACT)

Plasma samples were collected at different time points (n = 1503), and the median follow-up time was 28.

Whole-exome sequencing of each tumor and matched germline DNA

Before ACT treatment, postoperative ctDNA testing was performed on 218 patients, of which 9.

Carcinoembryonic antigen ( CEA ) and ctDNA were evaluated and compared to 155 postoperative patients .

Carcinoembryonic antigen ( CEA ) The definition of CEA recurrence-free survival (RFS) refers to the time from initial surgery to the earliest evidence of recurrence.

Effective treatment can cure some MRD-positive patients.

In general, the significance of longitudinal ctDNA analysis: 1.

Tenna V Henriksen, Noelia Tarazona, Thomas Reinert, et al.
Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients.
2021 ASCO GI, 11abs.


Leave a message here